Información del artículo
El Texto completo está disponible en PDF
Blbliografía
[1.]
The Impact-Rsv Study Group.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants..
Pediatrics, 102 (1998), pp. 531-537
[2.]
J.R. Groothuis.
Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial..
Pediatr Infect Dis J, 20 (2001), pp. 628-630
[3.]
s. Joffe, G.T. Ray, G.J. Escobar, S.B. Black, T.A. Lieu.
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants..
Pediatrics, 104 (1999), pp. 419-427
[4.]
J.H. Lofland, S.M. Touch, J.P. O'Connor, M.L. Chatterton, E.D. Moxey, L.E. Paddock, et al.
Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis..
Clin Ther, 22 (2000), pp. 1357-1369
[5.]
A. Marchetti, H. Lau, R. Magar, L. Wang, G. Devercelli.
Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savings..
Clin Ther, 21 (1999), pp. 752-766
[6.]
N.N. Dougherty, H.C. Meissner.
Respiratory syncytial virus immunoprophylaxis. Impact on epidemiology..
Paediatr Drugs, 2 (2000), pp. 127-132
[7.]
J.J. Buck, P. Debenham, R.C. Tasker.
Prophylaxis for respiratory syncytial virus infection: missing the target..
Arch Dis Child, 84 (2001), pp. 375
[8.]
S. Joffe, G.J. Escobar, S.B. Black, M.A. Armstrong, T.A. Lieu.
Rehospitalization for respiratory syncytial virus among preterminfants..
Pediatrics, 104 (1999), pp. 894-899
[9.]
T.P. Stevens, R.A. Sinkin, C.B. Hall, W.M. Maniscalco, K.M. McConnochie.
Respiratory syncytial virus and premature infants born at 32 week's gestation or earlier. Hospitalization and economic implications of prophylaxis..
Arch Pediatr Adolesc Med, 154 (2000), pp. 55-61
[10.]
M. Thomas, A. Bedford-Russell, M. Sharland.
Hospitalization rates for RSV infection in ex-preterm infants –implications for use of RSV immunoglobulin..
Arch Dis Child, 83 (2000), pp. 122-127
[11.]
X. Carbonell-Estrany, J. Quero, the IRIS Study Group.
Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons..
Pediatr Infect Dis J, 20 (2001), pp. 874-879
Copyright © 2002. Asociación Española de Pediatría
